SEC Form 4 · accession 0001209191-15-047187
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — SVP & Chief Scientific Officer
Period of report
May 26, 2015
Accepted (ET)
May 27, 2015 · 5:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 26, 2015 | M | 4,750 | $17.41 | A | 6,000 | D | |
| Common Stock | May 26, 2015 | S | 2,200 | $28.1115 | D | 3,800 | D | |
| Common Stock | May 26, 2015 | S | 2,550 | $28.03 | D | 1,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $17.41 | May 26, 2015 | M | 4,750 | D | — | May 20, 2024 | Common Stock | 4,750 | 55,250 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- F215,000 shares subject to the Option vested and became exercisable on May 21, 2015, and 1,250 shares subject to the Option vest monthly thereafter.